As the prices of cancer treatments are constantly rising, reaching tens and hundreds of thousands of euros per patient, this article examines the existence and impact of these prices in everyday hospital practice and in relation to medical autonomy. Our study takes place in the French health care system, which is characterized by the coverage of health care costs by the health insurance system. Through ethnographic observations carried out in hematology and thoracic oncology departments, the study explores how prices, although invisible and excluded from medical practice, can come into play in situations of tension at the boundaries of medical, administrative and financial prescriptive frameworks. However, this paper shows how the innovative and complex nature of these costly treatments can be reinterpreted in terms of value and even become a source of credit.
AbbottA. (1988). The system of professions: An essay on the division of expert labor. University of Chicago Press.
2.
AbecassisP.CoutinetN. (2017). Politique d’austérité et politique du médicament en France et au Royaume-Uni : une analyse de leurs répercussions sur le modèle de production pharmaceutique [Austerity policy and drug policy in France and the United Kingdom: An analysis of their impact on the pharmaceutical production model]. La Revue de l’Ires, 1(91–92), 111–140. https://doi.org/10.3917/rdli.091.0111
3.
AggarwalA.FojoT.ChamberlainC.DavisC.SullivanR. (2017). Do patient access schemes for high-cost cancer drugs deliver value to society? Lessons from the NHS Cancer Drugs Fund. Annals of Oncology, 28(8), 1738–1750. https://doi.org/10.1093/annonc/mdx110
4.
AltomonteG. (2020). Exploiting ambiguity: A moral polysemy approach to variation in economic practices. American Sociological Review, 85(1), 76–105. https://doi.org/10.1177/0003122419895986
5.
AronJ.GeeraertJ.IzambertC. (2021). L’accueil des patients étrangers à l’hôpital sous le feu croisé des réformes comptables et des politiques d’immigration [The admission of foreign patients in hospitals under the crossfire of accounting reforms and immigration policies]. Revue Française des Affaires Sociales, 4(4), 77–96. https://doi.org/10.3917/rfas.214.0077
6.
Assurance Maladie. (2017). Améliorer la qualité du système de santé et maîtriser les dépenses : les propositions de l’Assurance Maladie pour 2018 [Improving the quality of the healthcare system and controlling expenditure: The French assurance maladie's proposals for 2018. Assurance maladie’s annual proposal reports.]. Rapports annuels de propositions de l’Assurance Maladie.
7.
AustJ.CastelP.VézianA. (2019). Structurer la recherche française en cancérologie. Heurs et malheurs d’un projet réformateur [Structuring cancer research in France: Triumphs and challenges of a reformative project]. Presses de l’EHESP.
8.
BalcomS.DoucetS.DubéA. (2021). Observation and institutional ethnography: Helping us to see better. Qualitative Health Research, 31(8), 1534–1541. https://doi.org/10.1177/10497323211015966
9.
BeckerH. S. (1998). Tricks of the trade. How to think about your research while you’re doing it. The University of Chicago Press.
10.
BergM.HorstmanK.PlassS.Van HeusdenM. (2000). Guidelines, professionals and the production of objectivity: Standardisation and the professionalism of insurance medicine. Sociology of Health & Illness, 22(6), 765–791. https://doi.org/10.1111/1467-9566.00230
11.
BernalI.IráizozE. (2018). Cancer drugs: High prices and inequity. No es Sano Campain.
12.
BigotA.NegellenS.BretonT.IfrahN.DahanM.Hoog-LabouretN.BihanC. L.RopersJ. (2017). Le prix des médicaments anticancéreux. Etat des lieux et des connaissances / Soins [The price of anti-cancer drugs: Current status and knowledge / care, National Cancer Institute.]. Institut National du Cancer.
13.
BirchK.MuniesaF. (Eds.). (2020). Assetization: Turning things into assets in technoscientific capitalism. The MIT Press.
14.
BorupM.BrownN.KonradK.Van LenteH. (2006). The sociology of expectations in science and technology. Technology Analysis & Strategic Management, 18(3–4), 285–298. https://doi.org/10.1080/09537320600777002
15.
BrigandT.MaguetO.VerasJ.DurishP. (2020). Plaidoyer pour l’accès équitable aux nouvelles technologies de santé : le cas du Kymriah® [Advocacy for Equitable Access to New Health Technologies: The Case of Kymriah®]. Santé Publique, 5(32), 525–529. https://doi.org/10.3917/spub.205.0525
16.
BrownN. (2003). Hope against hype - Accountability in biopasts, presents and futures. Science and Technology Studies, 16(2), 3–21. https://doi.org/10.23987/sts.55152
17.
CassierM. (2023). Il y a des alternatives: une autre histoire des médicaments (XIXe-XXIe siècle) [There are alternatives: A different history of medicines (19th-21st Century)]. Seuil.
18.
CassierM.GaudillièreJ.-P. (2000). Recherche, médecine et marché: la génétique du cancer du sein [Research, medicine, and the market: The genetics of breast cancer]. Sciences Sociales et Santé, 18(4), 29–51. https://doi.org/10.3406/sosan.2000.1504
19.
CastelP. (2008). La gestion de l’incertitude médicale : approche collective et contrôle latéral en cancérologie [Managing medical uncertainty: Collective approach and lateral control in oncology]. Sciences Sociales et Santé, 26(1), 9–32. https://doi.org/10.3917/sss.261.0009
20.
ChabrolF.DavidP.-M.KrikorianG. (2017). Rationing hepatitis C treatment in the context of austerity policies in France and Cameroon: A transnational perspective on the pharmaceuticalization of healthcare systems. Social Science & Medicine, 187(1982), 243–250. https://doi.org/10.1016/j.socscimed.2017.03.059
21.
Cour des comptes. (2024). Chapitre 4 – Les medicaments anticancéreux: mieux regular en préservant un accès rapide aux traitements innovants [Anti-cancer drugs: Better regulation while preserving quick access to innovative treatments. annual report on social security]. Rapport annuel sur la Sécurité sociale.
22.
DewK.StubbeM.SignalL.StairmandJ.DennettE.KoeaJ.SimpsonA.SarfatiD.CunninghamC.BattenL.Ellison-LoschmannL.BartonJ.HoldawayM. (2015). Cancer care decision making in multidisciplinary meetings. Qualitative Health Research, 25(3), 397–407. https://doi.org/10.1177/1049732314553010
23.
EckouseS.LewisonG.SullivanR. (2008). Trends in the global funding and activity of cancer research. Molecular Oncology, 2(1), 20–32. https://doi.org/10.1016/j.molonc.2008.03.007
24.
EliasN. (1981). Qu’est-ce que la sociologie? [What is Sociology?]Pocket.
25.
FleckL. M. (2022). Precision medicine and the fragmentation of solidarity (and justice). Medicine, Healthcare & Philosophy, 25(2), 191–206. https://doi.org/10.1007/s11019-022-10067-2
26.
FloreJ.KokanovićR.BroomA.HeynemannS.Lai-KwonJ.JeffordM. (2023). Entanglements and imagined futures: The subject(s) of precision in oncology. Social Science & Medicine, 317(2), Article 115608. https://doi.org/10.1016/j.socscimed.2022.115608
27.
FreidsonE. (1988). Profession of medicine: A study of the sociology of applied knowledge. University of Chicago Press.
HassenteufelP. (1997). Les médecins face à l’État: une comparaison européenne [Doctors and the state: A European comparison]. Presses de Sciences po.
32.
HedgecoeA. (2004). The politics of personalised medicine: Pharmacogenetics in the clinic. Cambridge University Press.
33.
HillersdalL.SvendsenM. (2022). Cancer currencies: Making and marketing resources in a first-in-human drug trial in Denmark. In BremerA.StrandR. (Eds.), Precision oncology and cancer biomarkers. Issues at stake and matters of concern (pp. 45–60). Springer.
34.
IriartJ. A. B.GibbonS. (2023). Biomedical innovations, cancer care and health inequities: Stratified patienthood in Brazil. In BennettL. R.MandersonL.SpagnolettiB. (Eds.), Cancer and the politics of care: Inequalities and interventions in global perspective (pp. 23–41). UCL Press.
35.
JasanoffS.KimS.-H. (Eds.). (2015). Dreamscapes of modernity: Sociotechnical imaginaries and the fabrication of power. The University of Chicago Press.
36.
JolyP.-B. (2015). Le régime des promesses technoscientifique. In AudétatM. (Ed.), Pourquoi tant de promesses (pp. 31–48). Hermann.
37.
JuvenP.-A. (2016). Une santé [The Regime of Technoscientific Promises] In AudétatM.Why So Many Promises, (Ed.) qui compte ? Les coûts et les tarifs controversés de l’hôpital public [ Health that counts? Controversial public hospital costs and charges]. Presses Universitaires de France.
38.
JuvenP.-A. (2019). La valeur des médicaments. Calculs et controverses [The Value of Medicines: Calculations and Controversies]. In CastelP.JuvenP. A.VézianA., (Eds.), Les politiques de lutte contre le cancer en France. Quels regards sociologiques sur la régulation des pratiques médicales et des innovations? [Cancer Control Policies in France] (pp. 179–198) Presses de l’EHESP.
39.
JuvenP.-A.PierreF.VincentF. (2019). La casse du siècle. À propos des réformes de l’hôpital public [The heist of the century: public hospital reforms.]. Raisons d’agir.
40.
KerrA.ChekarC. K.RossE.SwallowJ.Cunningham-BurleyS. (2021). Personalised cancer medicine: Future crafting in the genomic era. Manchester University Press.
41.
KesselheimA. S.AvornJ.SarpatwariA. (2016). The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA, 316(8), 858–871. https://doi.org/10.1001/jama.2016.11237
42.
KityoC.CortesC. P.PhanuphakN.GrinsztejnB.VenterF. (2022). Barriers to uptake of long-acting antiretroviral products for treatment and prevention of HIV in low- and middle-income countries (LMICs). Clinical Infectious Diseases, 75(Suppl 4), S549–S556. https://doi.org/10.1093/cid/ciac752
43.
Kohli-LavenN.BourretP.KeatingP.CambrosioA. (2011). Cancer clinical trials in the era of genomic signatures: Biomedical innovation, clinical utility, and regulatory-scientific hybrids. Social Studies of Science, 41(4), 487–513. https://doi.org/10.1177/0306312711398741
44.
LakoffA. (2006). Pharmaceutical reason: Knowledge and value in global psychiatry. Cambridge University Press.
LightD. (2000). The medical profession and organizational change: From professional dominance to countervailing power. In Handbook of medical sociology, Vanderbilt University Press (pp. 201–2019). Prentice Hall.
47.
LivingstonJ. (2012). Improvising medicine: An African oncology ward in an emerging cancer epidemic. Duke University Press.
48.
MaraninchiD.VernantJ.-P. (2016, March 14). L’urgence de maîtriser les prix des nouveaux médicaments contre le cancer [The urgent need to control the price of new cancer drugs]. Le Figaro.
49.
McReynoldsC. J.KochL. C.RumrillP. D. (2001). Qualitative research strategies in rehabilitation. Work, 16(1), 57–65. https://doi.org/10.3233/WOR-2001-00125
50.
MiljkovićM. D.TuiaJ. E.OlivierT.HaslamA.PrasadV. (2022). Association between US drug price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration from 2015 to 2020. JAMA Internal Medicine, 182(12), 1319–1320. https://doi.org/10.1001/jamainternmed.2022.4924
51.
MukherjeeS. (2010). The emperor of all maladies: A biography of cancer. Scribner.
52.
NelsonN. C.KeatingP.CambrosioA. (2013). On being “actionable”: Clinical sequencing and the emerging contours of a regime of genomic medicine in oncology. New Genetics & Society, 32(4), 405–428. https://doi.org/10.1080/14636778.2013.852010
53.
NouguezÉ. (2016). Gouverner la concurrence par les prix [Governing the competition through prices]. In Dubuisson-QuellierS. (Ed.), Gouverner les conduites [Governing conducts] (pp. 229–262). Presses de Sciences Po.
54.
NouguezÉ. (2017). Des médicaments à tout prix [Drugs at all costs]. Presses de Sciences Po.
55.
NouguezÉ.BenoîtC. (2017). Gouverner (par) les prix. La fixation des prix des médicaments remboursés en France [Governing (through) prices. Setting prices for reimbursed drugs in France]. Revue Française de Sociologie, 58(3), 399–424. https://doi.org/10.3917/rfs.583.0399
56.
NovasC. (2006). The political economy of hope: Patients’ organizations, science and biovalue. BioSocieties, 1(3), 289–305. https://doi.org/10.1017/s1745855206003024
57.
PinellP. (1992). Naissance d’un fléau [Birth of a Plague]. Editions métailié.
58.
RavelliQ. (2015). La stratégie de la bactérie: une enquête au coeur de l’industrie pharmaceutique [The strategy of the bacteria: an investigation into the heart of the pharmaceutical industry]. Seuil.
59.
RodwinM. A.ManciniJ.DuranS.JalbertA.-C.ViensP.MaraninchiD.GonçalvesA.MarinoP. (2021). The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017. European Journal of Cancer, 145(1), 11–18. https://doi.org/10.1016/j.ejca.2020.11.031
60.
RøeO. D. (2017). The high cost of new cancer therapies—A challenge of inequality for all countries. JAMA Oncology, 3(9), 1169–1170. https://doi.org/10.1001/jamaoncol.2016.6335
61.
RollandC.SicotF. (2012). Les recommandations de bonne pratique en santé. Du savoir médical au pouvoir néo-managérial [Good practice recommendations in healthcare. From medical knowledge to neo-managerial power]. Gouvernement et action publique [Government and public action], 1(3), 53–75. https://doi.org/10.3917/gap.123.0053
62.
RoyV. (2020). A crisis for cures? Tracing assetization and value in biomedical innovation. In BirchK.MuniesaF. (Eds.), Assetization: Turning things into assets in technoscientific capitalism (pp. 97–124). The MIT Press.
63.
SchleidgenS.KlinglerC.BertramT.RogowskiW. H.MarckmannG. (2013). What is personalized medicine: Sharpening a vague term based on a systematic literature review. BMC Medical Ethics, 14(1), Article 55. https://doi.org/10.1186/1472-6939-14-55
64.
Secrétariat général de la commission des comptes de la sécurité sociale, Direction de la Sécurité sociale, Mission comptable permanente, & ACOSS. (2023). Les Comptes de la Sécurité Sociale.
65.
StarrP. (2017) The social transformation of american medicine: The rise of a sivereign profession & the making of a vast industry: With a new epiloque by the author (Updated edition). Basic Books.
66.
StraussA.ShizukoF.SuczekB.WienerC. (1985). Social organization of medical work. University of Chicago Press.
67.
TimmermannC. (2014). Introduction: The history of a recalcitrant disease. In TimmermannC. (Ed.), A history of lung cancer: The recalcitrant disease (pp. 1–10). Palgrave Macmillan UK.
68.
TimmermansS.BergM. (2003). The gold standard: The challenge of evidence-based medicine and standardization in health care. Temple University Press.
69.
TranvågE. J.StrandR. (2022). Rationing of personalised cancer drugs: Rethinking the co-production of evidence and priority setting practices. In BremerA.StrandR. (Eds.), Precision oncology and cancer biomarkers: Issues at stake and matters of concern (pp. 235–250). Springer International Publishing.
70.
TuttonR. (2014). Genomics and the reimagining of personalized medicine. Routledge & CRC Press.
71.
WadmannS.HaugeA. M. (2021). Strategies of stratification: Regulating market access in the era of personalized medicine. Social Studies of Science, 51(4), 628–653. https://doi.org/10.1177/03063127211005539
72.
WadmannS.HaugeA. M.Emdal NavneL. (2023). Good conduct in a context of rationing: A case study of how frontline professionals deal with distributive dilemmas of novel gene therapies. Sociology of Health & Illness, 45(3), 684–704. https://doi.org/10.1111/1467-9566.13608
73.
World Health Organization. (2018). Technical report: Pricing of cancer medicines and its impacts: A comprehensive technical report for the World Health Assembly.
